Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Predicting the critical quality attributes of ibuprofen tablets via modelling of process parameters for roller compaction and tabletting.

Matji A, Donato N, Gagol A, Morales E, Carvajal L, Serrano DR, Worku ZA, Healy AM, Torrado JJ.

Int J Pharm. 2019 Jun 30;565:209-218. doi: 10.1016/j.ijpharm.2019.05.011. Epub 2019 May 7.

PMID:
31075438
2.

Tuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers.

Serrano DR, Gordo MJ, Matji A, González S, Lalatsa A, Torrado JJ.

Pharmaceutics. 2019 Apr 4;11(4). pii: E167. doi: 10.3390/pharmaceutics11040167.

3.

New Drugs and Therapeutic/Diagnostic Targets for Fungal and Parasitic Diseases - Part I.

Dea-Ayuela MA, Serrano DR.

Curr Top Med Chem. 2018;18(15):1274. doi: 10.2174/156802661815181101110430.

PMID:
30598060
4.

New Drugs and Therapeutic/Diagnostic Targets for Fungal and Parasitic Diseases - Part II.

Dea-Ayuela MA, Serrano DR.

Curr Top Med Chem. 2018;18(16):1357. doi: 10.2174/156802661816181107142130.

PMID:
30497354
5.

Applying Loop-mediated Isothermal Amplification (LAMP) in the Diagnosis of Malaria, Leishmaniasis and Trypanosomiasis as Point-of-Care Tests (POCTs).

Dea-Ayuela MA, Galiana-Roselló C, Lalatsa A, Serrano DR.

Curr Top Med Chem. 2018;18(16):1358-1374. doi: 10.2174/1568026618666181025095735. Review.

PMID:
30360713
6.

A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tablets.

Alonso TR, Gagol A, Scherer M, Matji A, Torrado-Santiago S, Serrano DR, Garcia-Arieta A, Torrado JJ.

Patient Prefer Adherence. 2018 Sep 26;12:1927-1935. doi: 10.2147/PPA.S174479. eCollection 2018.

7.

Engineering of pharmaceutical cocrystals in an excipient matrix: Spray drying versus hot melt extrusion.

Walsh D, Serrano DR, Worku ZA, Madi AM, O'Connell P, Twamley B, Healy AM.

Int J Pharm. 2018 Nov 15;551(1-2):241-256. doi: 10.1016/j.ijpharm.2018.09.029. Epub 2018 Sep 14.

PMID:
30223079
8.

Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.

Smith L, Serrano DR, Mauger M, Bolás-Fernández F, Dea-Ayuela MA, Lalatsa A.

Mol Pharm. 2018 Jul 2;15(7):2570-2583. doi: 10.1021/acs.molpharmaceut.8b00097. Epub 2018 May 24.

PMID:
29762040
9.

Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?

de Pablo E, Fernández-García R, Ballesteros MP, Torrado JJ, Serrano DR.

Ann Transl Med. 2017 Nov;5(22):448. doi: 10.21037/atm.2017.09.17. Review.

10.

Production of cocrystals in an excipient matrix by spray drying.

Walsh D, Serrano DR, Worku ZA, Norris BA, Healy AM.

Int J Pharm. 2018 Jan 30;536(1):467-477. doi: 10.1016/j.ijpharm.2017.12.020. Epub 2017 Dec 11.

PMID:
29241701
11.

Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.

Serrano DR, Walsh D, O'Connell P, Mugheirbi NA, Worku ZA, Bolas-Fernandez F, Galiana C, Dea-Ayuela MA, Healy AM.

Eur J Pharm Biopharm. 2018 Mar;124:13-27. doi: 10.1016/j.ejpb.2017.11.015. Epub 2017 Dec 22.

PMID:
29196273
12.

Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful?

Konta AA, García-Piña M, Serrano DR.

Bioengineering (Basel). 2017 Sep 22;4(4). pii: E79. doi: 10.3390/bioengineering4040079. Review.

13.

A Comparative Study on the Performance of Inert and Functionalized Spheres Coated with Solid Dispersions Made of Two Structurally Related Antifungal Drugs.

Mugheirbi NA, O'Connell P, Serrano DR, Healy AM, Taylor LS, Tajber L.

Mol Pharm. 2017 Nov 6;14(11):3718-3728. doi: 10.1021/acs.molpharmaceut.7b00482. Epub 2017 Sep 29.

PMID:
28922604
14.

Engineering Synergistically Active and Bioavailable Cost-effective Medicines for Neglected Tropical Diseases; The Role of Excipients.

Serrano DR, Lalatsa A, Dea-Ayuela MA.

Curr Top Med Chem. 2017 Jul 19. doi: 10.2174/1568026617666170719164318. [Epub ahead of print]

PMID:
28730958
15.

Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting.

Fernández-García R, de Pablo E, Ballesteros MP, Serrano DR.

Int J Pharm. 2017 Jun 15;525(1):139-148. doi: 10.1016/j.ijpharm.2017.04.013. Epub 2017 Apr 8. Review.

PMID:
28400291
16.

Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.

Rolón M, Serrano DR, Lalatsa A, de Pablo E, Torrado JJ, Ballesteros MP, Healy AM, Vega C, Coronel C, Bolás-Fernández F, Dea-Ayuela MA.

Mol Pharm. 2017 Apr 3;14(4):1095-1106. doi: 10.1021/acs.molpharmaceut.6b01034. Epub 2017 Mar 3.

PMID:
28198632
17.

Analgesic and anti-inflammatory controlled-released injectable microemulsion: Pseudo-ternary phase diagrams, in vitro, ex vivo and in vivo evaluation.

Pineros I, Slowing K, Serrano DR, de Pablo E, Ballesteros MP.

Eur J Pharm Sci. 2017 Apr 1;101:220-227. doi: 10.1016/j.ejps.2016.12.030. Epub 2016 Dec 29.

PMID:
28042099
18.

Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals.

Serrano DR, Persoons T, D'Arcy DM, Galiana C, Dea-Ayuela MA, Healy AM.

Eur J Pharm Sci. 2016 Jun 30;89:125-36. doi: 10.1016/j.ejps.2016.04.030. Epub 2016 Apr 27.

PMID:
27131605
19.

Cocrystal habit engineering to improve drug dissolution and alter derived powder properties.

Serrano DR, O'Connell P, Paluch KJ, Walsh D, Healy AM.

J Pharm Pharmacol. 2016 May;68(5):665-77. doi: 10.1111/jphp.12476. Epub 2015 Sep 26.

PMID:
26408342
20.

Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials.

Serrano DR, Gallagher KH, Healy AM.

Curr Top Med Chem. 2015;15(22):2327-40. Review.

PMID:
26043733

Supplemental Content

Loading ...
Support Center